Skip to content

Nasdaq · CIK 0001799191

STLN Oncology Institute, Inc.

Insider trading from SEC Form 4. Last filing Mar 28, 2025.

Last 90 days

Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
11
with a Form 4 at this company

Signals

Open-market buys and sells at Oncology Institute, Inc., scored.

ScoreSideInsiderValueSharesHoldings changePrice contextFiled
65Notablebuy 5Richard A Barasch
director
$1.4M1,358,448+326%-
43Moderatebuy 5Robert Ross Carter
Chief Financial Officer
$9,4349,056+30%-
38Weakbuy 5Jeremy Castle
Chief Operating Officer
$9,4349,056+11%-
30Weakbuy 5Brad Hively
director
$9,4349,056+1%-
42Moderatebuy 5Karen Marie Johnson
director
$38k36,224+22%-
32WeakbuyBrad Hively
director
$50k300,000+82%-

Transactions

The last 35 rows filed, every code.

DateInsiderTransactionSharesPriceValueHoldings afterFiled
Mar 26, 2025Richard A Barasch
director
POpen-market purchase
Common Stockindirect: By LLC
+1,358,448$1.04$1.4M1,775,641Mar 28, 2025
Mar 26, 2025Robert Ross Carter
Chief Financial Officer
POpen-market purchase
Common Stock
+9,056$1.04$9,43439,407Mar 28, 2025
Mar 26, 2025Jeremy Castle
Chief Operating Officer
POpen-market purchase
Common Stock
+9,056$1.04$9,43490,386Mar 28, 2025
Mar 26, 2025Karen Marie Johnson
director
POpen-market purchase
Common Stock
+36,224$1.04$38k203,409Mar 28, 2025
Mar 26, 2025Brad Hively
director
POpen-market purchase
Common Stock
+9,056$1.04$9,434675,809Mar 28, 2025
Mar 26, 2025Richard A Barasch
director
POpen-market purchase
Common Warrantderivativeindirect: By LLC
+679,224$0.13$85k679,224Mar 28, 2025
Mar 26, 2025Karen Marie Johnson
director
POpen-market purchase
Common Warrantderivative
+18,112$0.13$2,26418,112Mar 28, 2025
Mar 26, 2025Brad Hively
director
POpen-market purchase
Common Warrantderivative
+4,528$0.13$5664,528Mar 28, 2025
Mar 26, 2025Jeremy Castle
Chief Operating Officer
POpen-market purchase
Common Warrantderivative
+4,528$0.13$5664,528Mar 28, 2025
Mar 26, 2025Robert Ross Carter
Chief Financial Officer
POpen-market purchase
Common Warrantderivative
+4,528$0.13$5664,528Mar 28, 2025
Mar 19, 2025Robert Ross Carter
Chief Financial Officer
DDisposition to issuer
Class A Common Stock
-1,150$0.89$1,02230,351Mar 20, 2025
Jan 6, 2025Robert Ross Carter
Chief Financial Officer
DDisposition to issuer
Class A Common Stock
-258$0.34$8631,501Jan 7, 2025
Dec 3, 2024Jeremy Castle
Chief Operating Officer
DDisposition to issuer
Common stock
-1,130$0.16$18181,330Dec 5, 2024
Nov 12, 2024Brad Hively
director
JOther
Common stock
-353,450$0.00$0366,753Dec 2, 2024
Nov 26, 2024Brad Hively
director
POpen-market purchase
Common stock
+250,000$0.17$43k616,753Dec 2, 2024
Dec 2, 2024Brad Hively
director
POpen-market purchase
Common stock
+50,000$0.15$7,500666,753Dec 2, 2024
Nov 22, 2024Mark L Pacala
director
AGrant or award
Common stock
+50,000$0.00$0134,409Nov 25, 2024
Nov 22, 2024Karen Marie Johnson
director
AGrant or award
Common stock
+52,000$0.00$0167,185Nov 25, 2024
Nov 22, 2024Anne McGeorge
director
AGrant or award
Common stock
+56,000$0.00$0183,346Nov 25, 2024
Nov 22, 2024Gabriel Ling
director
AGrant or award
Common stock
+40,000$0.00$0109,057Nov 25, 2024
Nov 22, 2024Mohit Kaushal
director
AGrant or award
Common stock
+56,000$0.00$0177,253Nov 25, 2024
Nov 22, 2024Brad Hively
director
AGrant or award
Common stock
+44,000$0.00$0720,203Nov 25, 2024
Nov 22, 2024Richard A Barasch
director
AGrant or award
Common stock
+80,000$0.00$0417,193Nov 25, 2024
Nov 20, 2024Robert Ross Carter
Chief Financial Officer
DDisposition to issuer
Class A Common Stock
-235$0.14$3231,759Nov 21, 2024
Nov 20, 2024Yale Podnos
Chief Medical Officer
DDisposition to issuer
Common stock
-1,709$0.14$23274,261Nov 21, 2024
Nov 20, 2024Daniel Virnich
Chief Executive Officer
DDisposition to issuer
Common stock
-4,750$0.14$646716,961Nov 21, 2024
Nov 20, 2024Yale Podnos
Chief Medical Officer
DDisposition to issuer
Common stock
-267$0.14$3673,994Nov 21, 2024
Nov 20, 2024Daniel Virnich
Chief Executive Officer
DDisposition to issuer
Common stock
-4,977$0.14$677711,984Nov 21, 2024
Nov 20, 2024Yale Podnos
Chief Medical Officer
DDisposition to issuer
Common stock
-1,026$0.14$14072,968Nov 21, 2024
Nov 12, 2024Daniel Virnich
Chief Executive Officer
JOther
Common stock
-78,094$0.00$0838,853Nov 18, 2024
Nov 12, 2024Mark L Pacala
director
JOther
Common stock
-20,248$0.00$0114,781Nov 18, 2024
Nov 12, 2024Yale Podnos
Chief Medical Officer
JOther
Common stock
-11,359$0.00$093,009Nov 18, 2024
Nov 12, 2024Daniel Virnich
Chief Executive Officer
JOther
Common stock
-117,142$0.00$0721,711Nov 18, 2024
Nov 12, 2024Mark L Pacala
director
JOther
Common stock
-30,372$0.00$084,409Nov 18, 2024
Nov 12, 2024Yale Podnos
Chief Medical Officer
JOther
Common stock
-17,039$0.00$075,970Nov 18, 2024

Insiders

Everyone who has filed a Form 4 here.

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

STLN insider trading: Oncology Institute, Inc. | InsiderTell